1 Min Read
Jan 10 (Reuters) - Gensight Biologics SA:
* GENSIGHT BIOLOGICS RECEIVES MHRA APPROVAL TO INITIATE PHASE I/II PIONEER CLINICAL TRIAL OF GS030 GENE THERAPY IN RETINITIS PIGMENTOSA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.